Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
That move comes alongside mixed short term returns as well as stronger performance over the past year. See our latest analysis for Dianthus Therapeutics. Recent trading has been choppy, with a 7 day share price return of 3.52% following a 30 day share price return decline of 9.35%, yet the 1 year total shareholder return of 65.76% points to momentum that has been building rather than fading. If Dianthus has caught your attention, it can be useful to see what else is moving in the sector, including other specialist healthcare stocks that might fit a similar profile. With Dianthus trading at US$38.19 against an analyst price target of US$63.63 and recent gains already strong, you have to ask yourself: is there still an opportunity here, or is the market already pricing in future growth? With Dianthus trading at US$38.19, its P/B ratio of 3x places it slightly above the broader US biotech industry but far below its closer peer set. P/B compares a company's market value to its
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Truist Financial Corporation from $56.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 11/5/25 - Miss
DNTH
Sec Filings
- 1/12/26 - Form 8-K
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- DNTH's page on the SEC website